AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML.

Acute myeloid leukemia (AML) is a fast-growing and often fatal blood cancer. One of the body's main defenses against it is a type of immune cell called a T cell, which can recognize and destroy cancer cells. But doctors have noticed something puzzling: T cells work well against some patients' leukemia cells, while other patients' leukemia cells seem to resist being killed entirely. In this study, researchers wanted to understand what makes the difference. They took leukemia cells from patients and exposed them to lab-engineered T cells designed to attack cancer. Using a technique called single-cell RNA sequencing — which lets scientists read which genes are switched on in individual cells — they compared leukemia cells and T cells before and after they interacted with each other. Two patterns emerged. Leukemia cells that were resistant to T cell attack had a distinct gene activity pattern, and this same pattern showed up more often in AML patients who had worse survival outcomes. These resistant cells essentially avoided the T cells altogether — they didn't even trigger a response. Leukemia cells that were sensitive to attack behaved very differently. Before being killed, they actively engaged with and activated the T cells. In doing so, they ramped up production of a protein called ICAM1. This protein is a key building block of what's known as the "immune synapse" — essentially the physical docking connection a T cell needs to lock onto its target and deliver a lethal signal. To test how important ICAM1 really was, the researchers removed it from leukemia cells that had previously been easy for T cells to kill. The result was striking: without ICAM1, these once-vulnerable leukemia cells became resistant to killing. This held true whether the attacking cells were naturally occurring T cells taken directly from the body or lab-engineered T cells, and it held true both in test tubes and in living animals. The takeaway is that ICAM1 acts like a molecular "handshake" — without it, T cells and leukemia cells simply don't connect well enough for the T cell to do its job. The researchers note that leukemia is a diverse disease, so ICAM1 is unlikely to be the only factor determining whether a patient's immune system can fight off their cancer. But it appears to be an important one, and it may help explain why some AML patients survive longer than others. This kind of insight could eventually help doctors predict which patients are likely to respond well to immune-based treatments, and might point toward new strategies — such as boosting ICAM1 levels — to make resistant leukemia cells more visible and vulnerable to the immune system.